Table 2 Baseline characteristics
From: Improving adherence to medication in adults with diabetes in the United Arab Emirates
Randomization Group | |||
|---|---|---|---|
Control | Intervention | ||
Age (mean +/− std) | 61a | 62a | |
+/− 11 | +/− 11 | ||
Gender | Female | 52.0 %a | 51.1%a |
116 | 114 | ||
Male | 48.0 %a | 48.9%a | |
107 | 109 | ||
Ethnicity | Arab Emarati | 53.8%a | 58.3%a |
120 | 130 | ||
Arab Non-Emarati | 40.8%a | 35.4 %a | |
91 | 79 | ||
Asian | 5.4 %a | 6.3 %a | |
12 | 14 | ||
HbA1c baseline (mean +/− std) | 8.50a | 8.49a | |
.09 | .10 | ||
SBP at baseline (mean +/− std) | 134a | 133a | |
26 | 26 | ||
DBP at baseline (mean +/− std) | 72a | 73a | |
20 | 21 | ||
HDL at baseline (mean +/− std) | 54a | 54a | |
11 | 11 | ||
LDL at baseline (mean +/− std) | 130a | 129a | |
36 | 37 | ||
TGL at baseline (mean +/− std) | 207a | 216b | |
42 | 41 | ||
Anti-Diabetic therapy | Monotherapy | 27.8%a | 30.9%a |
62 | 69 | ||
Combination | 72.2%a | 69.1%a | |
161 | 154 | ||
Insulin use | Yes | 49.8%a | 50.7 %a |
111 | 113 | ||
No | 50.2%a | 49.3%a | |
112 | 110 | ||
Prescence of Chronic conditions | Yes | 52.9%a | 55.2%a |
118 | 123 | ||
No | 47.1%a | 44.8%a | |
105 | 100 | ||